Key result
Etomidate-based anesthesia reduced the incidence of hypotension and other cardiovascular events compared to propofol in patients with coronary heart disease.
Why the study?
General anesthesia carries a heightened risk of perioperative cardiac complications and death in patients with CHD, making the choice of anesthetic strategy during major noncardiac surgery an important issue.
Does etomidate-based anesthesia reduce cardiovascular events and improve hemodynamic stability compared to propofol-based anesthesia in patients with stable coronary heart disease undergoing major noncardiac surgery?
RCT (n=80)
Triple-blind (patients, data collectors, and data analyzers)
Computer-generated random number table and sequentially numbered, opaque, sealed envelopes
No
Does etomidate-based anesthesia reduce cardiovascular events and improve hemodynamic stability compared to propofol-based anesthesia in patients with stable coronary heart disease undergoing major noncardiac surgery?
In patients with stable coronary heart disease undergoing major noncardiac surgery, etomidate-based anesthesia provides better hemodynamic stability and fewer intraoperative cardiovascular events than propofol-based anesthesia.
Answers are grounded in this paper and cite their sources.
Supports etomidate over propofol to minimize hypotension in stable CHD noncardiac surgery; extends RCT evidence on induction agent selection.
BACKGROUND: The ideal depth of general anesthesia should achieve the required levels of hypnosis, analgesia, and muscle relaxation while minimizing physiologic responses to awareness. The choice of anesthetic strategy in patients with coronary heart disease (CHD) undergoing major noncardiac surgery is becoming an increasingly important issue as the population ages. This is because general anesthesia is associated with a risk of perioperative cardiac complications and death, and this risk is much higher in people with CHD. AIM: To compare hemodynamic function and cardiovascular event rate between etomidate- and propofol-based anesthesia in patients with CHD. METHODS: This prospective study enrolled consecutive patients (American Society of Anesthesiologists grade II/III) with stable CHD (New York Heart Association class I/II) undergoing major noncardiac surgery. The patients were randomly allocated to receive either etomidate/remifentanil-based or propofol/remifentanil-based general anesthesia. Randomization was performed using a computer-generated random number table and sequentially numbered, opaque, sealed envelopes. Concealment was maintained until the patient had arrived in the operating theater, at which point the consulting anesthetist opened the envelope. All patients, data collectors, and data analyzers were blinded to the type of anesthesia used. The primary endpoints were the occurrence of cardiovascular events (bradycardia, tachycardia, hypotension, ST-T segment changes, and ventricular premature beats) during anesthesia and cardiac troponin I level at 24 h. The secondary endpoints were hemodynamic parameters, bispectral index, and use of vasopressors during anesthesia. CONCLUSION: In patients with CHD undergoing noncardiac major surgery, etomidate-based anesthesia is associated with fewer cardiovascular events and smaller hemodynamic changes than propofol-based anesthesia.
No takes yet. Share an insight, caveat, or question.
Dai et al. (2021) conducted an RCT in Coronary heart disease (CHD) undergoing major noncardiac surgery (n=80). Etomidate vs. Propofol (2.0 mg/kg induction, 1.5-3.0 μg/mL target-controlled infusion maintenance) was evaluated on Hypotension during anesthesia (one of the primary cardiovascular events) (p=0.027). Etomidate-based anesthesia reduced the incidence of hypotension and other cardiovascular events compared to propofol in patients with coronary heart disease.
Synapse has enriched 10 related papers. Consider them for comparative context: